Erasca Inc. Common Stock (ERAS)
Stock · NASDAQ · Health Care
$18.03as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$17.85
Industry
Biotechnology: Pharmaceutical Preparations
About ERAS
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12,…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 103
- Website
- www.erasca.com/
Fundamentals
- 1-day range
- $18$19.59
- Market cap
- $6.11B
- P/E (trailing)
- —
- P/E (forward)
- -30.19
- EPS (trailing)
- $-0.93
- Dividend yield
- —
- Beta
- 0.63
- Avg. volume
- 4.81M
52-week range
$1.33$24.28
Next earnings: November 11, 2026 · EPS estimate $-0.13After Closeconfirmed
Forecasts
10 analyst ratings
Buy 82%
Hold 18%
Sell 0%
1-year price forecast
High
$30
+66.4%
Median
$23
+27.6%
Low
$20
+10.9%
Erasca Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ERASErasca Inc. Common Stock$18.03▼ 7.49%Market cap $6.11BP/E —$1.33$24.28
- BLTEBelite Bio Inc American Depositary Shares$151.65▼ 3.42%Market cap $6.09BP/E —$62.18$200
- LGNDLigand Pharmaceuticals Incorporated Common Stock$280▼ 1.59%Market cap $5.85BP/E 38.07$158.4$326.63
- MIRMMirum Pharmaceuticals Inc. Common Stock$97.44▼ 2.32%Market cap $6.38BP/E —$63.23$130
- DNTHDianthus Therapeutics Inc. Common Stock$105.72▼ 5.22%Market cap $5.80BP/E —$22.81$117.88
- KNSAKiniksa Pharmaceuticals International plc Class A Ordinary Shares$78.1▼ 2.13%Market cap $5.73BP/E 75.29$33.25$82.94
- PTCTPTC Therapeutics Inc. Common Stock$70.01▼ 2.51%Market cap $5.68BP/E —$48.86$90.87
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ERAS Erasca Inc. Common Stock | $6.11B | — | $18.03 | ▼ 7.49% | $1.33$24.28 |
| BLTE Belite Bio Inc American Depositary Shares | $6.09B | — | $151.65 | ▼ 3.42% | $62.18$200 |
| LGND Ligand Pharmaceuticals Incorporated Common Stock | $5.85B | 38.07 | $280 | ▼ 1.59% | $158.4$326.63 |
| MIRM Mirum Pharmaceuticals Inc. Common Stock | $6.38B | — | $97.44 | ▼ 2.32% | $63.23$130 |
| DNTH Dianthus Therapeutics Inc. Common Stock | $5.80B | — | $105.72 | ▼ 5.22% | $22.81$117.88 |
| KNSA Kiniksa Pharmaceuticals International plc Class A Ordinary Shares | $5.73B | 75.29 | $78.1 | ▼ 2.13% | $33.25$82.94 |
| PTCT PTC Therapeutics Inc. Common Stock | $5.68B | — | $70.01 | ▼ 2.51% | $48.86$90.87 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Alger Mid Cap 40 ETF Q2 2026 Portfolio ReviewSeekingAlpha · 8/25/2026
- Erasca Announces FDA Granted Fast Track Designation To ERAS-0015 For Metastatic Pancreatic Adenocarcinomabenzinga · 8/24/2026
- B of A Securities Maintains Neutral on Erasca, Raises Price Target to $20Benzinga · 8/14/2026
- Guggenheim Maintains Buy on Erasca, Raises Price Target to $21Benzinga · 8/13/2026
- HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $22Benzinga · 8/12/2026
- Erasca Q2 EPS $(0.14) Misses $(0.11) EstimateBenzinga · 8/11/2026
Insider Activity
Insider Actions →Acquired
1.40M
Disposed
100.0K
- Fuchs Charles S. · August 10, 2026 · Grant1.30M
- Garner Ebun · April 1, 2026 · Option Exercise80.0K @ $1.7
- Garner Ebun · April 1, 2026 · Sale80.0K @ $16.4
- Morris Shannon · March 4, 2026 · Sale20.0K @ $15.04
- Morris Shannon · March 4, 2026 · Option Exercise20.0K @ $1.7
Institutional Ownership
March 31, 2026
- Total shares held
- 270.89M
- Total value held
- $3.97B
- Institutional holders
- 219
Top holders this quarter
- Unknown24.68M
- Unknown21.26M
- Unknown20.15M
- Unknown16.38M
- Unknown16.16M
- Unknown12.15M
- Unknown11.25M
- Unknown11.24M
- Unknown11.15M
- Unknown10.39M
See the full, filterable feed with live charts on the MarketWall dashboard.